Novavax outlined USD 200 million milestones. Novavax stock falls 2.71 percent

Published on 10/08/2026 at 17:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue fell 76.20 percent to USD 56.70 million in quarter two of 2026. Novavax stock costs EUR 9.71 on October 8, 2026 versus EUR 9.98.

Novavax outlined USD 200 million in potential near-term Sanofi milestones on September 10, 2026.
Second-quarter revenue fell 76.20 percent year over year to USD 56.70 million.
Novavax stock was at EUR 9.71 at Lang & Schwarz on October 8, 2026, down 2.71 percent versus EUR 9.98.

NVAX, US6700024010, Illustration mit AI erstellt.

Novavax, Inc. (ISIN US6700024010) had outlined USD 200 million in potential near-term Sanofi milestones on September 10, 2026, while Novavax stock fell 2.71 percent at Lang & Schwarz on October 8, 2026. As Investing.com reported, the milestones comprise USD 125 million linked to a potential Sanofi combination-vaccine trial and USD 75 million tied to technology transfer.

Three milestones shaped the story

On August 6, 2026, Novavax reported second-quarter revenue of USD 56.70 million and a net loss of USD 53.39 million. Benzinga said management also raised adjusted full-year 2026 revenue guidance to USD 235 million-275 million.

On August 28, 2026, Novavax said its XFG-adapted Nuvaxovid received approvals in the United States, European Union and Japan for the 2026-2027 vaccination season, according to the Novavax investor-relations page. On September 10, 2026, the company presented its partnership strategy at Citi's Biopharma Back to School Summit, with the potential USD 200 million milestone path as the latest dated figure.

What do the milestones change?

The figures point to a licensing model that can add cash without requiring Novavax to carry every commercial expense. The second-quarter product-sales figure was USD 19.00 million, up 76.00 percent year over year, while Sanofi-related revenue was USD 36.00 million, according to Benzinga.

The counterweight is the quarterly loss and the sharp revenue comparison with the prior year, when second-quarter revenue was USD 239 million. The guidance midpoint of USD 255 million for adjusted 2026 revenue therefore depends on partner royalties, milestones and the seasonal vaccine market rather than on a return to pandemic-era product sales.

Next report date is November 5

Zacks lists November 5, 2026 as the estimated date for Novavax's next earnings release. The same calendar gives a consensus loss estimate of USD 0.37 per share for the quarter ending September 2026.

Stock trades below its prior close

At Lang & Schwarz, the stock was trading at EUR 9.71 on October 8, 2026 at 5:42 p.m. CEST, down 2.71 percent versus the prior close of EUR 9.98 on October 7, 2026. Nasdaq data showed a separate last price of USD 10.88 at 11:44 a.m. ET on October 8, 2026, with a market capitalization of USD 1.8 billion.

The further course of trading is shown by the continuously updated real-time quote of Novavax stock.